Mallinckrodt Starts Phase II Duchenne Muscular Dystrophy Study but Will They Meet Recruitment Targets?

UK-based pharmaceutical company Mallinckrodt has announced that the first pediatric patient with Duchenne muscular dystrophy has been enrolled into the company’s Phase II trial of their investigational drug MNK-1411. The study will seek to test the safety and efficacy of MNK-1411 (also referred to as cosyntropin or tetracosactide) in patients between the ages of four and eight.